Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders; Management to Host Conference Call at 8

  • George Diaz

Press/Media

Period1 Apr 2019

Media coverage

1

Media coverage

  • TitleAeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders; Management to Host Conference Call at 8
    Media name/outletPrimeNewswire (Top News)
    Country/TerritoryUnited States
    Date1/04/19
    PersonsGeorge Diaz
View all 1
View less